V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20213996 | 20080354 | 1.79 | 118.3 | null | 2018-09-03 | 2018-09-09 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101572251 |
| 20213997 | 20080355 | 1.77 | 70.9 | Curative (C) | 2018-02-08 | 2018-02-23 | CAPECITABINE + CISPLATIN + Trastuzumab | null | Y | FLUOROURACIL + MITOMYCIN + RT | 101823329 |
| 20213998 | 20080356 | 1.76 | 61.7 | Palliative (P) | 2018-05-04 | 2018-12-23 | Cetuximab + FLUOROURACIL + FOLINIC ACID + IRINOTECAN | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100602368 |
| 20213999 | 20080357 | 1.6 | 93.2 | null | 2018-05-13 | 2018-06-12 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | null | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100348961 |
| 20214002 | 20080360 | 1.73 | 57.1 | Curative (C) | 2019-03-12 | 2019-05-20 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100792424 |
| 20214004 | 20080361 | null | 87.5 | Curative (C) | 2019-05-03 | 2019-05-26 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101459084 |
| 20214006 | 20080362 | 1.61 | 72.65 | Palliative (P) | 2019-08-11 | 2019-08-11 | IMATINIB | 02 | N | IMATINIB | 100763249 |
| 20214009 | 20080364 | 1.61 | 114 | Curative (C) | 2019-02-19 | 2019-03-06 | Cape+Cisplatin+Trastuzumab Load | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 101350456 |
| 20214010 | 20080365 | 1.59 | 72.8 | Palliative (P) | 2018-09-16 | 2018-09-30 | Cape+Cisplatin+Trastuzumab Load | 02 | N | TRIAL | 101644129 |
| 20214012 | 20080366 | 1.57 | 65.9 | Palliative (P) | 2018-01-14 | 2018-02-17 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101767452 |
| 20214014 | 20080367 | 1.71 | 58 | Palliative (P) | 2018-03-12 | 2018-04-08 | Trial Unspecified | Y | N | TRIAL | 101530346 |
| 20214015 | 20080368 | 1.66 | 87 | Palliative (P) | 2017-05-01 | 2017-05-02 | LANREOTIDE | 02 | N | LANREOTIDE | 100574682 |
| 20214016 | 20080369 | 1.9 | 111.5 | Curative (C) | 2018-04-29 | 2018-05-01 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100794647 |
| 20214018 | 20080371 | 1.85 | 92.5 | Palliative (P) | 2019-12-20 | 2019-12-22 | GO2 TRIAL | 01 | N | TRIAL | 101089923 |
| 20214019 | 20080372 | 1.78 | 63 | Disease modification (D) | null | 2018-09-10 | LANREOTIDE | 02 | N | LANREOTIDE | 100008911 |
| 20214021 | 20080373 | 1.58 | null | Palliative (P) | 2019-07-09 | 2019-07-16 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | LANREOTIDE | 101543561 |
| 20214022 | 20080374 | null | 0 | Curative (C) | 2018-02-25 | 2018-04-12 | FLUOROURACIL + MITOMYCIN + RT | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100116619 |
| 20214023 | 20080375 | 0 | 0 | Palliative (P) | 2016-09-01 | 2016-09-01 | Imatinib 400mg | 2 | N | IMATINIB | 101514901 |
| 20214027 | 20080377 | 1.7 | 71.2 | Palliative (P) | 2016-11-26 | 2016-12-03 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | TRIAL | 101660252 |
| 20214028 | 20080378 | 1.61 | 71.4 | Curative (C) | 2017-05-25 | 2017-05-31 | FLUOROURACIL + MITOMYCIN + RT | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101419679 |
| 20214029 | 20080379 | null | 73.6 | Palliative (P) | 2018-05-11 | 2018-05-11 | Trial Unspecified | 01 | N | TRIAL | 101617126 |
| 20214030 | 20080380 | 1.79 | 87.6 | Palliative (P) | 2018-11-17 | 2018-11-22 | HCX (Cape + Cisp + Tras) - Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100966403 |
| 20214031 | 20080381 | 1.75 | 71 | Palliative (P) | 2016-02-15 | 2016-02-28 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101769882 |
| 20214032 | 20080382 | 1.63 | 81 | Neo-adjuvant (N) | 2016-12-26 | 2016-12-28 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100325969 |
| 20214033 | 20080383 | 1.63 | 47.45 | Palliative (P) | 2018-10-26 | 2018-11-28 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | IMATINIB | 100904150 |
| 20214034 | 20080384 | 1.6 | 67 | Palliative (P) | 2019-04-16 | 2019-05-25 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101700801 |
| 20214035 | 20080385 | 0 | 98.6 | Disease modification (D) | 2017-03-16 | 2017-03-16 | IMATINIB | 02 | N | IMATINIB | 100319037 |
| 20214036 | 20080386 | 1.8 | 73.6 | null | 2016-12-16 | 2017-01-05 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | Y | TRIAL | 101172191 |
| 20214038 | 20080387 | 0 | 46 | Palliative (P) | 2019-03-01 | 2019-03-11 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100413268 |
| 20214039 | 20080388 | 1.54 | null | Palliative (P) | 2016-11-24 | 2016-12-15 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100271930 |
| 20214041 | 20080390 | 1.76 | 95 | Palliative (P) | 2018-09-19 | 2018-09-30 | Cetuximab + FOLFIRI cycle1 | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100571406 |
| 20214042 | 20080391 | 1.59 | 88 | Curative (C) | 2016-10-12 | 2016-10-13 | FLUOROURACIL + MITOMYCIN + RT | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101824379 |
| 20214043 | 20080392 | 1.69 | 73.2 | Palliative (P) | 2017-12-18 | 2018-01-06 | Trial Unspecified | 1 | N | TRIAL | 100719796 |
| 20214044 | 20080393 | 1.67 | 98.6 | Palliative (P) | 2018-09-05 | 2018-09-05 | Trial Unspecified | 02 | N | TRIAL | 101324065 |
| 20214045 | 20080394 | 1.8 | 80 | Palliative (P) | 2018-11-26 | 2018-12-10 | Cetuximab + FLUOROURACIL + FOLINIC ACID + IRINOTECAN | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101026645 |
| 20214046 | 20080395 | null | 120.4 | null | 2018-12-06 | 2018-12-07 | LANREOTIDE | 02 | null | LANREOTIDE | 101028782 |
| 20214048 | 20080397 | null | 72.8 | Palliative (P) | 2018-03-04 | 2018-03-18 | Cape+Cisplatin+Trastuzumab Load | 02 | N | LANREOTIDE | 100027128 |
| 20214049 | 20080398 | 0 | 71.5 | Palliative (P) | null | 2018-12-13 | LANREOTIDE | 02 | N | LANREOTIDE | 101243934 |
| 20214050 | 20080399 | 0 | 0 | Disease modification (D) | null | 2019-12-13 | GO2 TRIAL | Y | N | TRIAL | 101656047 |
| 20214054 | 20080403 | null | 61.4 | Curative (C) | 2019-04-30 | 2019-05-20 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101375904 |
| 20214055 | 20080404 | 1.69 | 56 | Palliative (P) | 2021-04-07 | 2021-04-17 | HCX | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101117768 |
| 20214056 | 20080405 | 1.6 | 71.8 | Adjuvant (A) | 2018-12-06 | 2018-12-10 | CAPECITABINE + CISPLATIN + Trastuzumab | null | N | TRIAL | 100582631 |
| 20214057 | 20080406 | 1.75 | 78 | Palliative (P) | 2019-11-30 | 2019-12-07 | Trial Unspecified | Y | N | TRIAL | 101630406 |
| 20214058 | 20080407 | 1.58 | 88 | Palliative (P) | 2019-01-06 | 2019-01-29 | HCX | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100780576 |
| 20214059 | 20080408 | 1.67 | 80 | Curative (C) | 2018-12-03 | 2018-12-17 | Fluorouracil+Mitomycin+RT (Anal Ca) | null | Y | FLUOROURACIL + MITOMYCIN + RT | 101849592 |
| 20214060 | 20080409 | 1.82 | 41 | Curative (C) | 2016-07-26 | 2016-07-26 | FLUOROURACIL + MITOMYCIN + RT | N | N | FLUOROURACIL + MITOMYCIN + RT | 101161973 |
| 20214061 | 20080410 | 1.49 | 64 | 03 | 2019-07-20 | 2019-07-20 | LANREOTIDE | 02 | N | LANREOTIDE | 101371668 |
| 20214062 | 20080411 | 1.55 | 90.8 | Palliative (P) | 2018-12-05 | 2018-12-28 | Cape+Cisplatin+Trastuzumab Load | 02 | N | LANREOTIDE | 100931402 |
| 20214063 | 20080412 | 1.8 | 0 | Palliative (P) | 2016-05-22 | 2016-06-06 | HCX | 02 | N | TRIAL | 100150716 |
| 20214064 | 20080413 | 1.73 | 61.7 | Palliative (P) | 2016-07-02 | 2016-07-16 | CAPECITABINE + CISPLATIN + Trastuzumab | 99 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101454451 |